Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 34

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 34
---
 the Company and our stockholders in light of, among other things, the Company’s ability to increase the trading price of our
Common Stock to meet the minimum stock price standards of The Nasdaq Capital Market without effecting the Reverse Stock Split, the per
share price of the Common Stock immediately prior to the Reverse Stock Split and the expected stability of the per share price of the
Common Stock following the Reverse Stock Split. If the Board determines that it is in the best interests of the Company and its stockholders
to effect the Reverse Stock Split, it will hold a Board meeting to determine the ratio of the Reverse Stock Split. For additional information
concerning the factors the Board will consider in deciding whether to effect the Reverse Stock Split, see “- Determination of the Reverse Stock Split Ratio” and “- Board Discretion to Effect the Reverse Stock Split.”

The text of the proposed
amendment to the Company’s Charter to effect the Reverse Stock Split is included as to this Proxy Statement (the
“Reverse Stock Split Charter Amendment”). If the Reverse Stock Split Proposal is approved by the Company’s stockholders,
the Company will have the authority to file the Reverse Stock Split Charter Amendment with the Secretary of State of the State of Delaware,
which will become effective upon its filing; provided, however, that the Reverse Stock Split Charter Amendment is subject to revision
to include such changes as may be required by the office of the Secretary of State of the State of Delaware and as the Board deems necessary
and advisable. The Board has determined that the amendment is advisable and in the best interests of the Company and its stockholders
and has submitted the amendment for consideration by our stockholders at the Special Meeting.

Reasons for the Reverse Stock Split

We are submitting this proposal
to our stockholders for approval in order to increase the trading price of our Common Stock to meet the minimum per share bid price requirement
for continued listing on The Nasdaq Capital Market. We believe increasing the trading price of our Common Stock may also assist in our
capital-raising efforts by making our Common Stock more attractive to a broader range of investors. Accordingly, we believe that the Reverse
Stock Split is in our stockholders’ best interests.

<div align='center'>22</div>

In addition, the Series Warrants include a provision that, conditioned
upon the receipt of Stockholder Approval as more fully described in Proposal No 1 – The Issuance Proposal, resets their respective
exercise price, subject to the Series A Floor Price and Series B